Cel-Sci Corp ( CVM ) - 1 Jahr vor dem "Start", der neue Thread (Seite 83)

[butcherfriend]

Da geht heute was-Irre Taxen vorbörslich

[Plaste]

Antwort auf Beitrag Nr.: 49.153.268 von Plaste am 23.02.15 21:23:35

Zitat von Plaste: http://www.thelifesciencesreport.com/pub/na/cel-sci-corp-s-n…" target="_blank" rel="nofollow ugc noopener">
http://www.thelifesciencesreport.com/pub/na/cel-sci-corp-s-n…

........
TLSR: Following the CRO purchase, there has been some concern regarding enrollment in the Multikine clinical trials, and speculation that the product does not work. Can you comment on the status of the related arbitration and the expected outcome?

GK: For full disclosure, I need to tell you that last year I significantly increased my position in CEL-SCI and am now a 10% holder in the company.

Cancer immunotherapy is super hot right now, with Phase 1 companies trading at up to $4B in market cap. We're a Phase 3 company with a current market cap of about $75M. I believe this is because people dropped our stock like a hot potato when they saw such slow enrollment in our clinical trial. Investors probably assumed that CEL-SCI would never finish the study and that Multikine did not work, leading to a very negative impact on our share price. But if you look at our current clinical trial enrollment, you would have to assume that Multikine does work. CEL-SCI's drug did not fail—there was only slow enrollment, which is now fixed with the new CRO..............

Übrigens bei 1,10 USD haben wir eine MK von 95,2 Mio
Da ist noch viel Platz bis 1 B oder mehr

[Plaste]

wichtige und Interessante Links

Information zur Studie finden Ihr unter:
https://www.clinicaltrials.gov/ct2/show/NCT01265849?term=mul…

Partner:
OEP Group: http://www.oep.com.tw/en-global/ams/business_en_2

Teva Pharmaceutical http://www.tevapharm.com/Pages/default.aspx

ERGOMED http://www.ergomedplc.com/co-development/deals/


Übrigens ist auf der Cel-Sci Homepage http://www.cel-sci.com/index.html auch ein schöner Film über "THE CEL-SCI STROY" zu finden...

[Plaste]

Zahl der Einschreibungen für Februar

Hallo Zusammen,

War es nicht ein schöner Freitag Nachbörslich noch mal auf 1,10 USD
Sollte es doch endlich so weit sein und die Richtung endgültig drehten...
Der Newsfloor seit Beginn des Jahres ist ziemlich beachtlich. G.K. ist auch ziemlich in die Offensive gegangen. Nach meiner Meinung ein sehr guter Schachzug.
Und ich denke morgen könnte es schon weiter gehen. Schließlich kommen meist um den 2. des Monats die Zahlen für die Anzahl der Einschreibungen.
Im US Board wird mit 30+ gerechnet. Bin mal gespannt.
Überhaupt ist dort immer mehr los, was darauf deutet das das Interesse an CVM weiter steigt. Gut so

Dann auf einen interessanten Montag

[barbarez69]

logo

NEWS RELEASE
Contact:
Gavin de Windt
CEL-SCI Corporation
[phone]
CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries

Belarus is 21st country to clear CEL-SCI's trial for patient enrollment
Vienna, VA, February 27, 2015 - CEL-SCI Corporation (NYSE MKT: CVM) today announced the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Belarus is the 21th country to approve CEL-SCI's Phase III trial.

"This means that CEL-SCI has now reached a key milestone in this pivotal Phase III clinical trial, receiving clearance in the planned 20 countries in addition to the United States. Well over 10 countries have been added to the study since we dismissed the prior clinical research organization (CRO). With the very large increase in enrollment in the study under the new CRO, we now also see strong interest from doctors and clinical centers in other countries too. Therefore, we are working on further expanding this global trial beyond the 21 countries in which we are already cleared to conduct the study. We expect that expanding the geography of the trial will yet further accelerate patient recruitment," stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine
Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. The Phase I trial started enrolling patients in September 2014. CEL-SCI also entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in HIV/HPV co-infected women and for peri-anal warts in HIV/HPV co-infected men and women.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the best way may be to activate the immune system of patients before they have received surgery, radiation and/or chemotherapy. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA.

CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. CEL-SCI received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for rheumatoid arthritis with researchers from Rush University Medical Center in Chicago, Illinois. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approvedfor sale, barter or exchangeby the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

When used in this report, the words "intends," "believes," "anticipated", "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




This email was sent to [e-mail] by [e-mail] |
Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.


CEL-SCI Corporation | 8229 Boone Blvd. | Suite 802 | Vienna | VA | 22182

[Plaste]

Flaherty Special Situation Newsletter z.T. CVM

http://archive.constantcontact.com/fs141/1101855435216/archi…

Wenn ich das richtig verstanden habe hat CVM für den Artikel Geld gezahlt.
Ob ich das nun gut heißen soll oder nicht.
Wir werden sehen.

Hoffen wir das ab next Week die 1 € hinter uns liegen.

LG Plaste

[Plaste]

http://www.thelifesciencesreport.com/pub/na/cel-sci-corp-s-n…" target="_blank" rel="nofollow ugc noopener">
http://www.thelifesciencesreport.com/pub/na/cel-sci-corp-s-n…

Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. That paradigm is changing, and CEL-SCI Corp. is among the companies poised to bring immunotherapy into these disease spaces. In this interview with The Life Sciences Report, Geert Kersten, CEL-SCI's CEO, describes how his company's Multikine and L.E.A.P.S. platforms can be deployed, and how investors can turn an immunotherapeutic win into profit.
Management Q&A: View From the Top

The Life Sciences Report: What makes CEL-SCI Corporation (CVM:NYSE.MKT) immunotherapy strategy stand out compared to more conventional chemotherapeutic approaches?

Geert Kersten: It's really two things. The first relates to when to boost the immune system for greatest therapeutic effect. We believe the immune system should be boosted while it's still healthy. More conventional approaches boost the immune system after it has been weakened by interventions such as surgery, radiation and chemotherapy. Boosting a healthy immune system is our key advantage.

"Our immunotherapy is a mass-produced vaccination that becomes specific for a person's tumor after it has been administered to the patient."

The second relates to directing the immune system specifically to the cancer. Our technology makes the immune system specific inside the body, whereas other technologies provide that specificity outside the body, by either taking a piece of a patient's tumor and making a vaccine from that or by using a monoclonal antibody that focuses on a subset of patients with a certain type of antigen. Our immunotherapy is a mass-produced vaccination that becomes specific for a person's tumor after it has been administered to the patient.

TLSR: Because of this approach, does CEL-SCI face competition from other cancer immunotherapy companies?

GK: No. Cancer immunotherapy companies, in general, are focusing on recurrent cancer patients, those whose tumors have come back. Their therapeutics are not meant for people who have just been diagnosed. Our approach, with Multikine (leukocyte interleukin injection), is intended to be the very first treatment a cancer patient receives, while approaches from other companies are often the last treatments. In addition, our initial target is head-and-neck cancer—an area not targeted by other cancer immunotherapy companies.

TLSR: Is the CEL-SCI immunotherapy platform intended for use at diagnosis, and independent of the stage of the cancer?

GK: Yes. In our clinical trial, we're treating people who have been diagnosed at stages III and IV. Those are late stages. A patient could be fairly advanced, but may not yet have had surgery, radiation and chemotherapy. We put ourselves in this space because even with late-stage cancers, the immune system remains relatively intact until surgery, radiation or chemotherapeutic interventions have been administered.

TLSR: How does the Multikine platform work?

GK: Multikine is composed of 14 cytokines naturally and continually produced by a healthy person. These cytokines are responsible for regulation of a healthy immune response. Multikine represents a copy of a healthy immune system that can be efficiently manufactured adhering to all regulatory requirements.

Multikine is injected in tiny doses around tumors to activate the immune system against the tumors, specifically the micrometastases—the tiny tumor cells that surround the tumor and go into the lymph nodes. This treatment can only be done for three weeks following diagnosis because, as an experimental therapy, it may not delay the proven therapies. Our Phase 2 studies, published in the Journal of Clinical Oncology, showed that in that three-week period, Multikine therapy completely eliminated tumors in 12% of patients.

"Head-and-neck cancer represents an unmet medical need and we have orphan drug status from the FDA."

Multikine is not designed for a specific patient or a specific cancer. Because of how it works, Multikine becomes personalized to the patient and specific to the tumor. We don't know of a single competing product that can do that. Multikine is basically a mass-produced and injectable cancer vaccine.

TLSR: Conceivably, all cancers could respond to immunotherapy. Why start with head-and-neck cancer?

GK: The last approval in advanced primary head-and-neck cancer was methotrexate, in 1954. That means there have been no new approvals in this indication in 61 years, and survival has barely improved. Head-and-neck cancer represents an unmet medical need and we have orphan drug status from the U.S. Food and Drug Administration (FDA). Head-and-neck cancer also represents 6% of the world's cancer cases.

TLSR: How is the Multikine Phase 3 clinical trial progressing?

GK: Our original clinical research organization (CRO) was acquired by a CRO owned by a private equity firm in a roll-up of multiple CROs, and we essentially lost the key people working on our study. This caused patient enrollment problems and many other problems. We are now working with a new CRO, which invested $10M of its own money in the study and will only get a return on that investment from sales of the product. We are enrolling new patients every single month in record numbers. We've increased our enrollments on the order of 2,000%, and are now in 20 countries. Our target is 880 patients, to have useful data from at least 780.

While we expect to complete enrollment of patients by the end of this year, we will be following patients beyond that, to show a survival rate increase of at least 10%. This will likely take us into 2017, with a potential launch date sometime in 2018.

TLSR: Following the CRO purchase, there has been some concern regarding enrollment in the Multikine clinical trials, and speculation that the product does not work. Can you comment on the status of the related arbitration and the expected outcome?

GK: For full disclosure, I need to tell you that last year I significantly increased my position in CEL-SCI and am now a 10% holder in the company.

Cancer immunotherapy is super hot right now, with Phase 1 companies trading at up to $4B in market cap. We're a Phase 3 company with a current market cap of about $75M. I believe this is because people dropped our stock like a hot potato when they saw such slow enrollment in our clinical trial. Investors probably assumed that CEL-SCI would never finish the study and that Multikine did not work, leading to a very negative impact on our share price. But if you look at our current clinical trial enrollment, you would have to assume that Multikine does work. CEL-SCI's drug did not fail—there was only slow enrollment, which is now fixed with the new CRO.

Because of the impact on our reputation, our stock price fell from $8/share to $0.60/share, at a time when other cancer immunotherapy stocks increased by hundreds of percent. This resulted in our need to issue more shares and absorb more dilution. However, if successful with our arbitration, we expect that our reputation will be repaired and that Wall Street will respond accordingly. If our reputation is repaired, I think our valuation will be closer to $1–2B.

The current arbitration is the result of damage to our reputation and market cap due to the very slow enrollment in our Phase 3 clinical trial. We took five months to prepare this arbitration and the CRO filed a motion to dismiss it. As the arbitrator rejected the motion to dismiss, our investors can be confident that the arbitration has merit. We have a trial date coming up very soon, and I believe that CEL-SCI will be able to show the world that the drug was not the problem.

TLSR: What's next on your agenda, after head-and-neck cancer?

GK: If head-and-neck cancer is all we ever succeed with, we will be a multibillion-dollar company. If we succeed in this Phase 3 trial, one might expect that Multikine will become part of the new standard of care. Reimbursement and use should be no problem. If we capture 25% of the total annual patient population of 600,000 (600K), CEL-SCI will treat 150K patients at an assumed price of $100K each. Even with 25% of the annual diagnoses, Multikine can capture $15 billion ($15B) in market share without addressing any other disease or indication.

But we have other potential targets. Right now, as a second indication, we're looking at human papilloma virus (HPV) in HIV-infected people. Like head-and-neck cancer, this is an unmet medical need with a $0.5–1B market.

With today's medications, HIV-infected people don't die from AIDS, but their immune systems continue to be weak. Consequently, if they pick up HPV, the No. 1 sexually transmitted disease, the HPV cannot be eliminated and all kinds of problems develop. Using Multikine in HIV-infected women, we demonstrated the ability to kill the majority of HPV strains, and also made HPV-related cervical lesions go away. As far as we know, no one has ever done that before in an HIV-infected patient.

"The L.E.A.P.S. technology allows you to control the type of immune response the body makes to an antigen."

Because of the HPV results, we entered into a cooperative research and development agreement with the U.S. Navy, allowing the navy to develop our product. Multikine is now being used at the San Diego Naval Base in HIV-infected people with anal warts—currently a big problem in the HIV-infected population. This demonstrates the potential broad utility of Multikine.

Someday, down the road, Multikine may have applications that we cannot even dream of today. We just have to make sure it gets to market.

TLSR: CEL-SCI is also developing a novel treatment for influenza. Is there underlying biology relating to cancer and influenza that makes both of these targets interesting to a single company?

GK: Quite honestly, Multikine may have applications against both cancer and viruses. However, L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is currently being developed to combat rheumatoid arthritis (RA). This is being done in collaboration with Rush University Medical Center in Chicago. Using the L.E.A.P.S. technology, we have produced extensive animal data showing protection against many diseases, including H1N1, malaria, tuberculosis, breast cancer, etc.

TLSR: How does flu mechanistically relate to RA? One is an infectious virus, and the other is an autoimmune disease.

GK: The L.E.A.P.S. technology allows you to control the type of immune response the body makes to an antigen. When you introduce an antigen into the body, it can induce the right kind of immune response or the wrong kind of immune response. If it makes the wrong kind, it can make a disease worse. With the L.E.A.P.S. technology, a peptide "rudder" is used to direct the immune system in the desired direction. If the rudder peptide induces a T-cell response, we can treat infectious diseases.

L.E.A.P.S. is essentially a disease-specific "antigen" peptide attached to a rudder peptide. The rudder peptide directs the way the antigen peptide is presented to the immune system to achieve the desired immune response. My hope is that L.E.A.P.S. will continue to show good results, allowing us to take it into the clinic and help people.

What people don't often understand is that it is not a weak immune system that makes you sick, it's the immune system making faulty responses. Think RA. Think lupus. Think Crohn's disease. Many diseases are caused by an immune system that's gone haywire. We think the L.E.A.P.S. technology is an opportunity to redirect the immune system from a faulty to a correct response.

TLSR: Anything else you'd like investors to know about CEL-SCI?

GK: I believe that Multikine will be the first nontoxic cancer therapy that actually works with the body. If successful against head-and-neck cancer, Multikine could potentially be used to treat breast cancer, melanoma, cervical cancer and many other cancers and diseases that we can't even think of today. That is our vision.

TLSR: Thank you for your time.

Geert Kersten, chairman and CEO of CEL-SCI Corporation, has served in his current leadership role since 1995. He has been with CEL-SCI since its inception in 1987, and has been involved in the pioneering field of cancer immunotherapy for almost two decades. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law, and has a unique vision of how the company's Multikine product will change the way cancer is treated. Prior to CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble, and at Source Capital, an investment banking firm. He is a native of Germany, graduated from Millfield School in England and completed his studies in the U.S. His undergraduate degree is in accounting. He also received a master's degree in business administration from George Washington University, and a law degree from American University in Washington, D.C.

Read what other experts are saying about:

CEL-SCI Corporation

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Interviews page.

DISCLOSURE:
1) Daniel E. Levy conducted this interview for Streetwise Reports LLC, publisher of The Gold Report, The Energy Report, The Life Sciences Report and The Mining Report, and provides services to Streetwise Reports as an independent contractor. He or his family owns shares of the company mentioned in this interview: None.
2) CEL-SCI Corp. paid Streetwise Reports to conduct, produce and distribute the interview.
3) Geert Kersten had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Geert Kersten and not of Streetwise Reports or its officers.
4) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview until after it publishes.

[Plaste]

Hallo Zusammen.

Hat jemand am gestrigen Conference call teilgenommen?

Hier eine kurze Zusammenfassung von clone14me aus dem US Board:

clone14me • 4 hours ago

0 users liked this posts users disliked this posts 1
Reply

Todays Conference Call

IMO, today's call was a gift from Geert to investors. A reassurance of sorts the company and it's technolgies are on course. In no way was this call disigned as a commerical hook for institutional investors. Geert spoke the truth as he has lived it. He deserved a higher quality of follow-up questions. Geert came accross very well with a clear and concise explaination of where the company is today. Perhaps once P-3 is fully enrolled Geert will reward longtime shareholders, those who did not sell all of thier shares before the split in order to gain via the shareholder protection plan whereby shareholders of record as of 2007(?) would be rewarded the right to purchase additional shares at an abridged cost if the company were to be taken over.It would be great if these shareholders were given additional benefits. Sure liked how he responded to last caller. No doubt dilution will take place prior to the completion of P-3 as I would not expect a settlement above 15m. Lot's of unanswered question today, but that's the fault of shareholders. Great Job, Geert"

unter folgendem Link könnt Ihr Euch den Call runterladen:

https://www.dropbox.com/s/94pms2u182dvo3h/Ascendiant%20Manag…

Auf Grund meines miserabelen englischs habe ich mich dort nicht geäußert. Aber wäre schön wenn noch jemand sich den Call anhören könnte und eine deutsche Zusammenfassung posten würde.

LG und schönes WE Plaste

[Plaste]

CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time

Vienna, VA, February 20, 2015 - CEL-SCI Corporation (NYSE MKT: CVM), a late stage cancer immunotherapy company,announced that Geert Kersten, Chief Executive Officer, will participate in Ascendiant's Quarterly Management Discussion Series teleconference today, Friday, February 20, 2015, at 11 AM ET.

Interested parties may access the call by dialing [phone] and entering passcode 216781. A replay webcast link will be available on the investor relations section of www.cel-sci.com shortly after the call concludes.
About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA (Cooperative Research and Development Agreement).

CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. The Company has recently received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for RA with researchers from Rush University Medical Center in Chicago, Illinois. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

[Plaste]

Wer gestern den Kurs verfolgt hatte brauchte gute Nerven.
Erst bis 1,08 USD hoch gezogen und dann runtergeprügelt auf einen SK 0,922 USD
Schön war das ja nicht, aber das Volumen von 2.495.580 Stk. war schon beachtlich.
Wie ich mir schon dacht tut sich wohl was.
Werden einige Aktien über den Markt „getauscht“, wird wegen einer anstehenden KE vielleicht versucht den Kurs in Richtung Norden zu schieben ?
Überm großen Teich wird u.a. spekuliert das die Shorties am Werk sind…. Wobei ich denke das kann bei CVM ziemlich gefährlich werden, da wir in diesem Jahr ganz andere Voraussetzungen haben. Wir werden sehen.

Die 20 Länder - haben wir schon
Über 350 Einschreibunge – haben wir schon

Wie viel Zentren sind es überhaupt jetzt? Ich glaube 100 Stk. waren geplant.

LG an alle

PS: Ich wäre zufrieden wenn wir nex Week langfristig die 1 USD überwinden könnten.